Friday's bash-a-thon put IMUC in a completely oversold position. I rest assured that the recent news and the Brian Nichols article on the Russell global/3000/Microcap indexes will turn the price around substantially and swiftly.
"ImmunoCellular Therapeutics (IMUC) was not expected to be added to any of the Russell indexes, seeing as how the company just uplisted to the NYSE on May 30. However, it was added to the Global, 3000, and Microcap indexes, which should be good for this company as it has no institutional ownership and very little insider ownership due to it being an OTC stock prior to last week. There was most likely a lack of funds from buying shares in anticipation since the list addition was unexpected, which almost certainly was what helped drive other stocks higher. Therefore, as the stock is accumulated over the next two weeks in the open market, it could become a nice performer."